News stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have trended somewhat positive on Monday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.86099497644 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge (zacks.com)
- Eiger Biopharmaceuticals (EIGR) Lifted to “Hold” at ValuEngine (americanbankingnews.com)
- Eiger Biopharmaceuticals Inc (EIGR) to Post FY2017 Earnings of ($3.88) Per Share, Wedbush Forecasts (americanbankingnews.com)
- Eiger Biopharmaceuticals Inc (EIGR) Expected to Post Earnings of -$1.07 Per Share (americanbankingnews.com)
Eiger Biopharmaceuticals (NASDAQ EIGR) opened at $13.15 on Monday. The company has a market capitalization of $140.97, a P/E ratio of -2.48 and a beta of 2.54. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19. Eiger Biopharmaceuticals has a 52-week low of $6.10 and a 52-week high of $13.95.
EIGR has been the topic of several research analyst reports. ValuEngine raised Eiger Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Oppenheimer reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Eiger Biopharmaceuticals in a research note on Monday, September 25th. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Monday, October 16th. Roth Capital initiated coverage on Eiger Biopharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Wedbush reissued a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.43.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.